Israel-based cancer diagnostic tests company Nucleix has secured CE mark for the marketing of its Bladder EpiCheck test in the European Union (EU) countries.

Designed to aid urologists to monitor patients with bladder cancer, Bladder EpiCheck contains a panel of 15 DNA methylation biomarkers to detect the disease.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The proprietary biomarkers are said to be multiplexed in a real-time PCR analysis.

"These are important milestones for bladder cancer patients and urologists, adding an additional tool to their arsenal fighting bladder cancer."

Nucleix co-founder and chief executive officer Elon Ganor said: "We are very proud with this regulatory approval and with the study results.

"These are important milestones for bladder cancer patients and urologists, adding an additional tool to their arsenal fighting bladder cancer.

"It is a proof of Nucleix's unique scientific innovations in epigenetics.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"These results show best-in-class performance for Bladder EpiCheck and will strongly support our launch in Europe starting these days during the annual meeting of the European Association of Urology."

The regulatory approval is based on the results from a clinical study conducted at select urology centres in Europe.

The multi-centre, prospective and blinded study was performed in more than 400 patients who were enrolled in their first year of follow up.

The results were reported as a comparision of the Bladder EpiCheck with the current gold standard follow up sequence of cystoscopy, cytology and pathology for the positives.

The study indicated that the test has 99% negative predictive value (NPV, excluding Ta-LG patients), 92% sensitivity (excluding Ta-LG patients) and 88% specificity.